GlassScriptPhysician profile
Ronald Glover Henry
NPI 1306806088
$5,282.27
in general payments reported to CMS, 2019-2025
39 companies · $57.89 in 2025
The $57.89 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $316 · 2021: $1,253 · 2022: $1,380 · 2023: $927 · 2024: $40.58 · 2025: $57.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $761.24 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $739.35 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $521.08 | 2019-2023 | |
| Abbvie INC. | $473.77 | 2019-2023 | |
| Antares Pharma, INC. | $322.71 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Endo Pharmaceuticals INC. | $233.81 | 2019-2023 | Xiaflex, Aveed |
| Allergan, INC. | $182.14 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $181.78 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $179.21 | 2021 | |
| Axonics, INC. | $168.97 | 2020-2023 | Axonics |
| Myriad Genetic Laboratories, INC. | $165.21 | 2021-2023 | Bracanalysis Cdx, Prolaris |
| Myovant Sciences INC. | $151.74 | 2022 | |
| Coloplast Corp | $148.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $123.76 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $122.02 | 2019-2023 | Bard Urinary Drainage Bag |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $110.16 | 2021 | |
| Urovant Sciences INC | $98.44 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $73.56 | 2021-2023 | Oxlumo |
| Bayer Healthcare Pharmaceuticals INC. | $55.61 | 2022-2023 | |
| Rochester Medical Corporation | $47.46 | 2021-2022 | |
| Therapeuticsmd, INC. | $44.03 | 2019-2020 | |
| Halozyme INC | $40.05 | 2023 | |
| Olympus America INC. | $27.10 | 2019 | |
| Procept Biorobotics Corporation | $26.52 | 2022 | |
| Medtronic, INC. | $25.30 | 2022 | |
| Agiliti Surgical, INC. | $23.66 | 2019 | |
| Telix Pharmaceuticals | $23.61 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $23.00 | 2019 | |
| Tolmar, INC. | $22.84 | 2023 | |
| Convatec INC. | $22.34 | 2022 | |
| Travere Therapeutics, INC. | $20.54 | 2019 | |
| Caris Mpi, INC. | $19.24 | 2025 | Mi Cancer Seek |
| Boston Scientific Corporation | $18.68 | 2019 | |
| Merck Sharp & Dohme LLC | $17.89 | 2023 | Lynparza, Keytruda |
| Hollister Incorporated | $16.82 | 2023 | Onli |
| Dendreon Pharmaceuticals LLC | $16.37 | 2019 | |
| Clarus Therapeutics INC. | $12.88 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.